PharmaJet partner, Nykode Therapeutics announces phase 1/2 clinical trial with next generation DNA-based COVID-19 vaccine candidates

GOLDEN, Colo. — December 14, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants. The DNA-based vaccines will be delivered intramuscularly in the clinical trial exclusively using the PharmaJet Stratis® Needle-free Injection System.

PharmaJet Named Asia’s Most Innovative Vaccine Delivery System at the Vaccine World Asia Congress 2021

GOLDEN, Colo. — November 30, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, has been named “Asia’s Most Innovative Vaccine Delivery System” at the Asia-Pacific Vaccine Excellence Awards 2021 (AVEA 2021). The award was accepted by Paul LaBarre, MS, MBA, Vice President, Global Business Development, PharmaJet, Inc.

PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress

GOLDEN, Colo. — November 15, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17. The presentation, entitled Improving Vaccine Performance with Needle-free Delivery, is being presented by Paul LaBarre, MS, MBA, Vice President, Global Business Development.

PharmaJet , WHO and BMGF conduct Somalia Polio Vaccination Campaign

GOLDEN, Colo. — October 21, 2021 - PharmaJet®the maker of innovative, needle-free injection technology, today announced that its Tropis® intradermal needle-free injection system is being used in a campaign in Somalia delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in part by the Bill and Melinda Gates Foundation, using PharmaJet’s needle-free delivery product, supplied by the World Health Organization (WHO), is to ensure children under 5 who missed their routine immunization, receive their full regimen of inactivated polio vaccine.

PharmaJet Presents Needle-free delivery of COVID-19 Vaccines and Beyond at World Vaccine Congress – Europe

GOLDEN, Colo. — October 12, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest partnerships and research results will be presented at the World Vaccine Congress - Europe on October 21. The presentation, entitled Needle-free Delivery: COVID-19 Vaccines and Beyond, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc.

EClinical Medicine

Study published in EClinicalMedicine confirms safety and immunogenity of world’s first Needle-free COVID-19 DNA vaccine

Zydus Cadila (Cadila Healthcare Limited) published the results from their Phase I clinical study evaluating the safety and immunogenicity of their COVID-19 DNA vaccine, delivered using the PharmaJet Tropis Needle-free Injection System. The ZyCoV-D vaccine is comprised of plasmid DNA carrying the spike gene from SARS-CoV-2 and was initially evaluated in mouse, guinea pig, and…

PharmaJet partner Zydus Cadila announces Emergency Use Authorization approval for world’s first plasmid DNA COVID-19 vaccine

GOLDEN, Colo. — August 23, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine, ZyCoV-D, is exclusively administered using the PharmaJet Tropis® Needle-free Injection System.

PharmaJet partner Zydus Cadila seeks EUA on world’s first plasmid DNA COVID-19 vaccine

GOLDEN, Colo. — July 7, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19. The vaccine, ZyCoV-D, will be exclusively administered using the PharmaJet Tropis® Needle-free Injection System. Zydus Cadila is a global pharmaceutical company based in India, that develops, manufactures, and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines.

Update: PharmaJet Needle-free COVID-19 Vaccine Trial

GOLDEN, Colo. — June 30, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2. COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with and Melbourne-based biotech Technovalia. The PharmaJet System was chosen due to its record of increasing the effectiveness of DNA vaccines, ease-of-use, and speed of the delivery system compared to traditional needle and syringe.